Journals / Van Tıp Dergisi / 2022 / Cilt: 29 - Sayı: 2

Is Lactate Dehydrogenase An Important Mortality Predictor in Covid-19 Patients with Atrial Fibrillation?

Atrial Fibrilasyonlu Covid-19 Hastalarında Laktat Dehidrogenaz Mortalitenin Önemli Bir Göstergesi midir?

Pages
141–148
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

High LDH levels need careful observation to help prevent potential complications in COVID-19 subjects presenting with AF.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Abnormal laboratory parameters can be detected in severe patients with COVID-19, which are associated with adverse outcomes.
📊
Key Findings & Data:Increased lactate dehydrogenase (LDH) is usually associated with tissue damage.
💡
Conclusion & Impact:High LDH levels need careful observation to help prevent potential complications in COVID-19 subjects presenting with AF.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Abnormal laboratory parameters can be detected in severe patients with COVID-19, which are associated with adverse outcomes. Increased lactate dehydrogenase (LDH) is usually associated with tissue damage. Cardiovascular disease is a common comorbidity in COVID-19 disease. In the current report, the objective was to examine the relationship between LDH levels and atrial fibrillation (AF) in COVID-19 patients. Materials and Methods: This investigation involved a retrospective and cross-sectional study. A total of 195 consecutive COVID-19 [45 AF (+) and 150 AF (-)] subjects were enrolled in the study. COVID-19 cases were determined from analysis of an oropharyngeal/nasopharyngeal swab using RT-PCR. LDH, procalcitonin, and D-dimer were recorded from the hospital records. Results: Fatal patients had higher LDH levels compared to non-fatal patients (470±144 vs 404±60). A significant positive association was determined for LDH and troponin, CRP, and procalcitonin in all study subjects and AF patients. An LDH level of 443 was identified as the cut -off point in mortality of AF patients with a sensitivity and specificity of 73% and 74% (AUC= 0.744), respectively. LDH (OR: 1.009) and age (OR: 1.238) were shown to independently predict mortality in COVID-19-AF patients. Conclusions: Increased LDH levels were essential predictor of mortality in COVID-19 subjects with AF. High LDH levels need careful observation to help prevent potential complications in COVID-19 subjects presenting with AF.

Özet

Giriş: Ciddi COVID-19 hastalarında olumsuz olaylar ile ilişkili anormal laboratuvar parametreleri tespit edilebilmektedir. Yüksek laktat dehidrogenaz (LDH) düzeyleri genellikle doku hasarı ile ilişkilidir. Kardiyovasküler hastalık COVID-19 hastalarında yaygın bir komorbid durumdur. Bu çalışmanın amacı COVID-19 hastalarında LDH düzeyleri ile atriyal fibrilasyon (AF) arasındaki ilişkiyi incelemektir. Yöntem ve Gereçler: Bu çalışma retrospektif ve kesitsel bir araştırmayı içermektedir. Çalışmaya ardışık 195 COVID-19 hastası [45 AF (+) ve 150 AF (-)] dahil edildi. COVID-19 tanısı RT-PCR kullanılarak bir orofarenks/nazofarenks sürüntü analizi ile belirlendi. LDH, prokalsitonin ve D-dimer düzeyleri hastane kayıtlarından kaydedildi. Bulgular: Mortal hastalar, mortal olmayan hastalara kıyasla daha yüksek LDH seviyelerine sahipti (470±144'a karşı 404±60). Çalışmaya dahil edilen tüm hastalarda ve AF hastalarında LDH ile troponin, CRP ve prokalsitonin arasında anlamlı bir pozitif ilişki saptandı. AF hastalarının mortali tesinde 443 (U/l) LDH düzeyi sırasıyla %73 ve %74'lük bir duyarlılık ve özgüllükle (AUC= 0.744) sınır değer olarak saptandı. COVID- 19-AF hastalarında LDH (OR: 1.009) ve yaş (OR: 1.238) mortalitenin bağımsız prediktörü olduğu belirlendi. Tartışma ve Sonuç: Yüksek LDH düzeyleri COVID-19 AF hastalarında mortalitenin önemli bir prediktörüdür. AF ile başvuran COVID-19 hastalarında olası komplikasyonların önlenmesine yardımcı olmak için yüksek LDH düzeylerinin dikkatle gözlemlenmesi gerekmektedir.

🔖

Cite This Article

ASOĞLU, E., ASOĞLU, R. (2022). Is Lactate Dehydrogenase An Important Mortality Predictor in Covid-19 Patients with Atrial Fibrillation?. Van Tıp Dergisi, Cilt: 29 - Sayı: 2, 141–148. https://ajindex.com/articles/645894

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet 2020;395(10223):514-523
  2. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. In Springer; 2017. p 529- 539
  3. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708-2000
  4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama 2020;323(11):1061-1069
  5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet 2020;395(10223):497-506
  6. Aloisio E, Chibireva M, Serafini L, Pasqualetti S, Falvella FS, Dolci A, et al. A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity. Arch Pathol Lab Med 2020; 144(12):1457-1464
  7. Shi J, Li Y, Zhou X, Zhang Q, Ye X, Wu Z, et al. Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study. BMC Med 2020;18(1):1- 6
  8. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med 2020;201(11):1372-1379
  9. Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J 2020;41(19):1821-1829
  10. EpiCentro. Characteristics of COVID-19 patients dying in Italy [Internet]. [cited 2020 Sep 16]. Available from: Available from: https://www.epicentro.iss.it/en/coronaviru s/sars-cov-2-analysis-of-deaths 11. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel Coronavirus in the United States. N Engl J Med 2020;382(10):929-936
  11. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37(38):2893- 2962
  12. Marini J, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA 2020;323(22):2329-2330
  13. Choi KW, Chau TN, Tsang